Social Links

Follow on Facebook Follow on TwitterFollow EiR on PinterestFollow EiR on Instagram

Xpert Access


Login To Get Involved!

Forgot your username?

Forgot your password?


Join Us At EiR Now!

DNRS Roof Banner


Universal AJAX Live Search

Search - Categories
Search - Contacts
Search - Content
Search - Newsfeeds
Search - Weblinks

Hormonal Treatment Of Depression With Phenylethylamine (PEA)







PEA treatment rapidly restores well-being.

Mild as well as severe forms of depression may have a simple cause, and a simple cure. A brain hormone, phenylethlamine (PEA), promotes energy and elevates mood. A deficiency in PEA renders the person weak, tired, sluggish, and depressed. Taking PEA rapidly restores well-being. PEA is a natural, physiological treatment of depression.

Our clinical observations indicate that 60% of depressed patients have a reduction in PEA metabolism, and that PEA is effective in 60% of depressed patients. PEA relieves depression very fast, in a matter of hours or days, and produces no toxic effects, tolerance or abuse.

In other words, depression is an illness very much like diabetes. In diabetes there is a (relative) deficiency of insulin, and it is treated by administering insulin. An even closer analogy is hypothyroidism. Thyroid hormones sustain bodily energy; their deficit produces a characteristic syndrome that includes depression in the adult, and mental retardation in the child. Likewise 2-phenylethylamine (PEA) is a neurohormone that sustains psychological energy. A large group of depressions, sixty percent of them, it seems, are due to a (relative) deficit in PEA, and can be treated by giving PEA.

Fortunately, unlike insulin, PEA can be taken by mouth. However, PEA is rapidly destroyed in the body. To prevent its rapid destruction, it must be protected by the simultaneous administration of low doses of selegiline (Eldepryl), a medication used in elderly people to slow down the progress of Parkinson disease.

PEA controls depression in 60% of depressed persons--the same percentage as all major antidepressants such as Prozac--but it is less toxic.

PEA is by no means a panacea that controls all depressions, but it may deserve to be used as the first treatment to try because it acts fast, and it can be used for long periods of time without fear of harmful consequences such as weight gain, sexual inhibition, and other common side effects of antidepressant drugs. This is because PEA replacement is a physiological treatment of depression.


Advantages of PEA Treatment Over Other Current Treatments for Depression

PEA controls depression in 60% of depressed persons--the same percentage as all major antidepressants such as Prozac--but it is less toxic.

Although there are many treatments for depression, PEA treatment has four advantages over current treatments.

PEA acts very rapidly, in a matter of hours or days, instead of weeks. A rapid treatment for depression would be an extremely useful tool to reduce disability, to shorten medical treatment, and to prevent suicide. Particularly important is the fact that PEA is very effective in bipolar patients, as this illness represents a high risk for suicide.

PEA practically has no side effects or toxicity; selegiline is given at very small doses, as used to slow down the progress of Parkinson's disease in the elderly.

PEA treatment is effective in types of depression that do not respond well to standard antidepressants; in turn, standard pharmacological agents act in depressions for which phenylethylamine is not effective.

Because PEA directly restores a neurohormone that is in deficit, it may be more effective and less likely to have long-term toxic effects than medications which have more complex and indirect actions.

Particularly important is the fact that PEA is very effective in bipolar patients, as this illness is life long.




Research Studies on the use of PEA in Depression
General References

Sabelli, H. (2002). Phenylethylamine deficit and replacement in depressive Illness. In D. Mishooulon and J.F. Rosenbaum. (Eds.), Natural medications for psychiatric disorders. (pp 83-110), Baltimore: Lippencott Williams and Wilkins.
Sabelli, H. (2000). Aminoacid precusors for depression. Psychiatric Times, 17. 42-49
PEA controls depression in 60% of depressed persons--the same percentage as all major antidepressants such as Prozac--but it is less toxic.
Sabelli, H. (1998). Phenylethylamine replacement as a rapid and physiological treatment for depression. Psycheline, 2,(3), 32-39.
Sabelli, H., Fink, P., Fawcett, J. and Tom, C. (1996). Sustained antidepressant effect of PEA replacement. Journal of Neuropsychiatry and Clinical Neurosciences, 8, 168-171.
Sabelli, H.C and Javaid J.I. (1995). Phenylethylamine modulation of affect: Therapeutic and diagnostic implications. Journal of Neuropsychiatry and Clinical Neurosciences, 7, 6-14.
Sabelli, H.C., Fahrer, R, Doria Medina R, and Ortiz Frágola E. (1994). Phenylethylamine replacement rapidly relieves depression. Journal of Neuropsychiatry, 6, 203.


The reduction in PEA metabolism in 60 % of depressed patients has been demonstrated in over 200 patients.

Sabelli, H.C, Fawcett, J, Gusovsky, F, et al. (1983). Urinary phenylacetate: a diagnostic test for depression? Science, 220, 1187-1188.

Sabelli, H.C., Fawcett, J, Gusovsky, F. et al (1986). Clinical studies on the phenylethylamine hypothesis of affective disorder, Journal of Clinical Psychiatry, 47, 66-70.
Sabelli, H., Javaid, J., Fawcett, J. and Kravitz, H. (1990). Urinary phenylacetic acid in panic disorder with and without depression, Acta Psychiatrica Scandinavica, 82, 14-16.
Sabelli, H., Carlson-Sabelli, L., Levy, A. and Patel, M. (1995). Anger, fear, depression and crime: Physiological and psychological studies using the process method. In Robertson and Combs (Eds.), Chaos Theory in the Life Sciences. (pp 65-88), Mahwah, New Jersey: Erlbaum.


This reduction in PEA metabolism with depression has been confirmed by three other research groups who studied psychiatric patients.

Sandler, et al, in the UK, 1979, (Clin Chim Acta, 93,169-171.
Gonzalez-Sastre in Spain, 1988, Acta Psychiatrica Scandinavica, 78,208-210.
Tsugi, et al, in Japan, 1986, Anal Biochem, 153,116-120.

and by

A.B. Levy in her 1991 study of 146 jail inmates ( A Clinical Study of the Urinary Phenylacitic Acid (PAA) Test of Depression in Prison Inmates, Brigham Young University.


Please Help Support EiR with a Positive Google Review!

Review on Google


If you like EiR and / or enoyed this content; please help us keep going by leaving a Positive Google Review: 

P.S. This is entirely secure, we collect no data other than what is freely available from Google and you can remain anonymous!


Related Articles:


People in this conversation

Leave your comments

Post comment as a guest

0 Character restriction
Your text should be more than 25 characters
Your comments are subjected to administrator's moderation.
terms and condition.